Modern approaches for evaluating treatment effect heterogeneity from clinical trials and observational data

Author:

Lipkovich Ilya1ORCID,Svensson David2ORCID,Ratitch Bohdana3ORCID,Dmitrienko Alex4ORCID

Affiliation:

1. Advanced Analytics and Access Capabilities Eli Lilly and Company Indianapolis Indiana USA

2. Statistical Innovation, BioPharmaceuticals R&D AstraZeneca Gothenburg Sweden

3. Clinical Statistics and Analytics, Research & Development, Pharmaceuticals Bayer Inc. Mississauga Ontario Canada

4. Department of Biostatistics Mediana San Juan Puerto Rico USA

Abstract

In this paper, we review recent advances in statistical methods for the evaluation of the heterogeneity of treatment effects (HTE), including subgroup identification and estimation of individualized treatment regimens, from randomized clinical trials and observational studies. We identify several types of approaches using the features introduced in Lipkovich et al (Stat Med 2017;36: 136‐196) that distinguish the recommended principled methods from basic methods for HTE evaluation that typically rely on rules of thumb and general guidelines (the methods are often referred to as common practices). We discuss the advantages and disadvantages of various principled methods as well as common measures for evaluating their performance. We use simulated data and a case study based on a historical clinical trial to illustrate several new approaches to HTE evaluation.

Publisher

Wiley

Reference230 articles.

1. Tutorial in biostatistics: data‐driven subgroup identification and analysis in clinical trials;Lipkovich I;Stat Med,2017

2. FDA (U.S. Food and Drug Administration).FDASIA Section 907: Inclusion of Demographic Subgroups in Clinical Trials.2018.

3. EMA (European Medicines Agency).Guideline on the investigation of subgroups in confirmatory clinical trials.2019.

4. FDA (U.S. Food and Drug Administration).Draft Guidance for Industry: Diversity Plans to Improve Enrollment of Participants From Underrepresented Racial and Ethnic Populations in Clinical Trials.2022.

5. Personalized medicine: four perspectives of tailored medicine;Ruberg SJ;Stat Biopharma Res,2015

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3